11/8/26 Learning More from Less: Smarter Design and Execution in Rare Disease Trials Previous Designing Neuromuscular Trials for Successful Execution: The Role of Specialized CROs, Sites and Clinical Research Vendors Next Pediatric Rare Disease Development: Evidence, Flexibility, and Regulatory Pathways You Might Also Like Write Your Own Endpoint Justification Commercial Success in Rare Disease Takes an Ecosystem: Aligning Manufacturers, Specialty Pharmacy, Providers, and Patient Support Platform and Basket Trials in Rare Disease: What’s Working, What Isn’t, and What It Takes to Scale Mock Formal FDA Meeting: How to Respond When FDA Disagrees The Plausible Mechanism Pathway: A New Evidence Playbook for Rare Disease Development
11/8/26 Learning More from Less: Smarter Design and Execution in Rare Disease Trials Previous Designing Neuromuscular Trials for Successful Execution: The Role of Specialized CROs, Sites and Clinical Research Vendors Next Pediatric Rare Disease Development: Evidence, Flexibility, and Regulatory Pathways You Might Also Like Write Your Own Endpoint Justification Commercial Success in Rare Disease Takes an Ecosystem: Aligning Manufacturers, Specialty Pharmacy, Providers, and Patient Support Platform and Basket Trials in Rare Disease: What’s Working, What Isn’t, and What It Takes to Scale Mock Formal FDA Meeting: How to Respond When FDA Disagrees The Plausible Mechanism Pathway: A New Evidence Playbook for Rare Disease Development
